Aktienanalyse zu Bone Biologics Corp (BBLG)BBLGBone Biologics Corp

Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Bone Biologics Corp (BBLG) is not a good buy right now due to its poor financial performance and negative market trends. The stock has a current price of $0.61, a year-to-date change of -60.06%, and a 1-year change of -70.99%. Additionally, the RSI is at 28.146, indicating that the stock is oversold, but this may not be a strong enough signal to warrant a buy given the overall downward trend. The main risk is the company's ongoing losses, with a net income of -4153506 USD in Q3 2024 and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term.